• Ceftolozane/Tazobactam: A Targeted Response to Gram-Negative

  2026-04-30

  This review analyzes the innovative mechanism and clinical data for ceftolozane/tazobactam, a cephalosporin/β-lactamase inhibitor combination with enhanced activity against multidrug-resistant Gram-negative pathogens. The findings clarify its pharmacological profile, efficacy in severe infections, and implications for resistance management.

• Aztreonam: Applied Protocols for Gram-Negative Research

  2026-04-30

  Aztreonam, a synthetic monocyclic β-lactam antibiotic, provides researchers with optimized workflows for targeting Gram-negative aerobic bacteria and probing drug metabolism. This guide translates cutting-edge reference findings into actionable protocols, advanced troubleshooting, and data-driven tips for reproducible, high-impact experiments.

• Levofloxacin: Synthetic Fluoroquinolone for Advanced Assays

  2026-04-29

  Levofloxacin’s dual action as a synthetic fluoroquinolone antibiotic and modulator of bone-cartilage biology empowers multidomain research, from bacterial DNA replication inhibition to osteoblast and chondrocyte functional studies. This guide translates recent resistance epidemiology and workflow intelligence into actionable, troubleshooting-rich protocols for maximizing experimental impact.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence and Research

  2026-04-29

  A pivotal phase 3 trial demonstrates that mavorixafor, an oral CXCR4 antagonist, significantly improves neutrophil and lymphocyte counts in patients with WHIM syndrome—a rare immunodeficiency—while reducing infection rates. The study sets a new benchmark for targeted therapies in rare hematological disorders, and its findings have implications for both clinical research and precision medicine approaches.

• Calpeptin: Precision Calpain Inhibitor for Fibrosis Research

  2026-04-28

  Calpeptin stands apart as a nanomolar calpain inhibitor, delivering reproducible performance in pulmonary fibrosis and inflammation research. This guide unpacks experimental workflows, troubleshooting, and advanced applications that maximize Calpeptin’s utility for translational studies.

• CPSIT_0844 Drives IL-6/IL-8 via TLR2/TLR4 and NF-κB in Monoc

  2026-04-28

  This study identifies the Chlamydia psittaci inclusion membrane protein CPSIT_0844 as a potent inducer of inflammatory cytokines IL-6 and IL-8 in human monocytes. By dissecting the TLR2/TLR4-MyD88–MAPK/NF-κB axis, the research clarifies a key mechanism underlying C. psittaci immunopathology and informs targeted approaches for inflammatory signaling pathway research.

• Synergistic CDK4/6 and BET Inhibition Suppresses Pancreatic

  2026-04-27

  Gu et al. reveal that combining CDK4/6 and BET inhibitors synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-to-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. This work highlights a promising therapeutic strategy and offers mechanistic insight into overcoming limitations of single-agent CDK4/6 inhibition.

• Canagliflozin Alters Mitochondria in Diabetic Kidney Disease

  2026-04-27

  This study demonstrates that canagliflozin, a selective SGLT2 inhibitor, enhances mitochondrial structure and function in proximal tubular cells of hypertensive–diabetic mice. The findings reveal mechanisms beyond glycemic control, suggesting mitochondrial remodeling as a contributor to renal protection in diabetic kidney disease.

• Inhibition of CaN/FoxO1/FABP4 Axis Prevents Foam Cell Format

  2026-04-26

  The referenced study delineates how SERCA2 dysfunction accelerates atherosclerosis via the calcineurin/FoxO1/FABP4 pathway in macrophages, leading to enhanced lipid accumulation and foam cell formation. Targeting this axis—particularly FABP4 inhibition—restores lipid metabolism and reduces atherosclerotic lesion development, informing new therapeutic strategies.

• CSBTA Pharmacokinetics and Tissue Distribution in MASH Model

  2026-04-25

  This study systematically characterizes the pharmacokinetic variability and hepatic distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice with metabolic dysfunction-associated steatohepatitis (MASH). By integrating UHPLC-MS/MS quantification and transporter/metabolic enzyme profiling, the research provides mechanistic insights for rationalizing dosing regimens in MASH and related metabolic disease models.

• Angiotensin III: Precision Peptide for RAAS and Cardiovascul

  2026-04-24

  Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe) is unlocking advanced cardiovascular and neuroendocrine research through its robust pressor and aldosterone-inducing actions. With exceptional solubility and validated receptor selectivity, this APExBIO peptide empowers reproducible, high-resolution modeling of RAAS signaling and disease mechanisms.

• Indometacin Sodium Trihydrate: Precision Tools for Prostagla

  2026-04-24

  Explore the scientific versatility of Indometacin Sodium Trihydrate in inflammation and myelin regeneration assays. This article uniquely deciphers its protocol parameters and cross-domain potential, offering actionable guidance for precision anti-inflammatory research.

• Assay Reliability with Coagulation Factor II (Thrombin) B Ch

  2026-04-23

  This article addresses core reproducibility and data quality challenges in cell-based and coagulation assays, focusing on the validated use of Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] (SKU A1057). Through scenario-driven Q&A, it guides biomedical researchers in optimizing workflow reliability and experimental sensitivity using this high-purity, assay-ready reagent.

• m6A RNA Modification: Antagonistic Plant-Virus Interactions

  2026-04-23

  This study uncovers a mutually antagonistic mechanism involving N6-methyladenosine (m6A) RNA modification in plant-virus interactions. By dissecting how host and viral factors modulate m6A deposition and recognition, the research provides new insights into the molecular arms race that shapes plant antiviral immunity and viral pathogenicity.

• Gepotidacin Phase 2 Study: Efficacy for Uncomplicated Gonorr

  2026-04-22

  The referenced phase 2 trial evaluates gepotidacin, a novel bacterial type II topoisomerase inhibitor, as a single-dose oral therapy for uncomplicated urogenital gonorrhea. The study demonstrates high efficacy and safety, addressing the urgent need for alternatives to current antibiotic regimens amid rising resistance.

455 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page